Search details
1.
Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer.
Invest New Drugs
; 31(3): 760-8, 2013 Jun.
Article
in English
| MEDLINE | ID: mdl-22907596
2.
An Open-Label, Multicenter, Phase I/II Study of JNJ-40346527, a CSF-1R Inhibitor, in Patients with Relapsed or Refractory Hodgkin Lymphoma.
Clin Cancer Res
; 21(8): 1843-50, 2015 Apr 15.
Article
in English
| MEDLINE | ID: mdl-25628399
3.
Carlumab, an anti-C-C chemokine ligand 2 monoclonal antibody, in combination with four chemotherapy regimens for the treatment of patients with solid tumors: an open-label, multicenter phase 1b study.
Target Oncol
; 10(1): 111-23, 2015 Mar.
Article
in English
| MEDLINE | ID: mdl-24928772
4.
Cloning and expression of rat coagulation factor VII.
Thromb Res
; 109(4): 225-31, 2003 Feb 15.
Article
in English
| MEDLINE | ID: mdl-12757778
5.
Enhancement of paclitaxel and carboplatin therapies by CCL2 blockade in ovarian cancers.
Mol Oncol
; 8(7): 1231-9, 2014 Oct.
Article
in English
| MEDLINE | ID: mdl-24816187
6.
Development of a rapid streptavidin capture-based assay for the tyrosine phosphorylated CSF-1R in peripheral blood mononuclear cells.
Int J Biol Sci
; 9(10): 1099-107, 2013.
Article
in English
| MEDLINE | ID: mdl-24339731
7.
Utilizing pharmacokinetics/pharmacodynamics modeling to simultaneously examine free CCL2, total CCL2 and carlumab (CNTO 888) concentration time data.
J Clin Pharmacol
; 53(10): 1020-7, 2013 Oct.
Article
in English
| MEDLINE | ID: mdl-23878055
8.
A first-in-human, first-in-class, phase I study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 in patients with solid tumors.
Cancer Chemother Pharmacol
; 71(4): 1041-50, 2013 Apr.
Article
in English
| MEDLINE | ID: mdl-23385782
Results
1 -
8
de 8
1
Next >
>>